Page 30 - MemoriaCIBER2019-ENG

30
CIBER Annual report 2019
• NaTBiL: PDT based on nanoconjugates triggered by biolight,with the participation of the group led by JM López-Hidalgo and collaboration with CIBERONC.
In addition, during the year 2019, four ongoing Early Stage projects have continued being developed, corresponding to their second year of execution, led by CIBER contracted researchers:
• CARDIOGRAFET II: Disposable sensing platform based on graphene-SGFET to monitor biomarkers for cardiac diseases II. Coordinator: Elisabet Prats.
• Nano-MEA: Nanoparticle drug delivery systems for the improvement of the chronically implanted microlectrode-array viability. Coordinator: Cristina Soto.
• NANORASI: Optogenetic approach to visual rehabilitation using nanoparticle vectors. Coordinator: Lawrence Humphreys.
• Lyfe4AD: Comprehensive approach of non-adherent patients through an mHealth environment in people with endocrine diseases. Coordinator: Carmen Pérez Gandía.
In the session dedicated to young researchers during the CIBER-BBN Annual Conference, researcher David Hernando, from the group led by Pablo Laguna, received the award for the best article in the field of Bioengineering for his work entitled Validation of Heart rate polar monitor RS800 for heart rate variability analysis during exercise.
The activity of the Programme in European initiatives has been marked by the granting of the Graphene Flagship Core Project 3, whose applicant has been Rosa Villa, from the group led by J. Aguiló. In addition, seven new proposals currently pending resolution have been requested.
In the activity at the national level, we highlight the Juan de la Cierva grant received by the researcher in training Alba Martín Yebra from Pablo Laguna’s group.
Biomaterials
and Advanced Therapies
Coordinator: Julio San Román del Barrio
From the Biomaterials and Advanced Therapies Programme, six intramural collaboration proposals were added in 2019, three of them with groups from other thematic areas of CIBER (CIBERER and CIBERONC). Cancer has been the most frequently addressed topic, followed by infectious diseases, neuromuscular diseases and sleep disorders. To these proposals we must add the 32 that were presented in 2018 and which have been developed throughout 2019.
During 2019, the nine Early Stage projects have been developed for the second year running, coordinated by CIBER staff in groups from the Biomaterials and Advanced Therapies Programme. Their titles and coordinators are as fo- llows:
• COAT-EBM: Bioactive coatings to promote osseointegration of personalized 3D porous titanium prosthe- ses, Leonor Santos.
• OCUSySTEM: Mesenchymal stem cells as a next generation drug delivery system for ocular surface disea- ses, Teresa Nieto Miguel.
• SMEW: Therapeutic microparticles functionalized with stem cell secretome for chronic skin wound healing, Soledad Pérez-Amodio.
• 3DHEPPEG: 3D bioprinting of novel heparin-PEG hydrogel for regenerative therapies, Miguel Ángel Mateos Timoneda.
• HYDROREG: Engineering hydrogels to promote muscle regeneration, Patricia Rico.
• tMELANO: Clinical validation of a novel temperature sensor based in bilayer organic material to help in melanoma diagnostic, Sara Oliván.